The Rheumatologist
COVID-19 NewsACR Convergence
  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed
  • Home
  • Conditions
    • Rheumatoid Arthritis
    • SLE (Lupus)
    • Crystal Arthritis
      • Gout Resource Center
    • Spondyloarthritis
    • Osteoarthritis
    • Soft Tissue Pain
    • Scleroderma
    • Vasculitis
    • Systemic Inflammatory Syndromes
    • Guidelines
  • Resource Centers
    • Axial Spondyloarthritis Resource Center
    • Gout Resource Center
    • Psoriatic Arthritis Resource Center
    • Rheumatoid Arthritis Resource Center
    • Systemic Lupus Erythematosus Resource Center
  • Drug Updates
    • Biologics & Biosimilars
    • DMARDs & Immunosuppressives
    • Topical Drugs
    • Analgesics
    • Safety
    • Pharma Co. News
  • Professional Topics
    • Ethics
    • Legal
    • Legislation & Advocacy
    • Career Development
      • Certification
      • Education & Training
    • Awards
    • Profiles
    • President’s Perspective
    • Rheuminations
    • Interprofessional Perspective
  • Practice Management
    • Billing/Coding
    • Quality Assurance/Improvement
    • Workforce
    • Facility
    • Patient Perspective
    • Electronic Health Records
    • Apps
    • Information Technology
    • From the College
    • Multimedia
      • Audio
      • Video
  • Resources
    • Issue Archives
    • ACR Convergence
      • Gout Resource Center
      • Axial Spondyloarthritis Resource Center
      • Psoriatic Arthritis
      • Abstracts
      • Meeting Reports
      • ACR Convergence Home
    • American College of Rheumatology
    • ACR ExamRheum
    • Research Reviews
    • ACR Journals
      • Arthritis & Rheumatology
      • Arthritis Care & Research
      • ACR Open Rheumatology
    • Rheumatology Image Library
    • Treatment Guidelines
    • Rheumatology Research Foundation
    • Events
  • About Us
    • Mission/Vision
    • Meet the Authors
    • Meet the Editors
    • Contribute to The Rheumatologist
    • Subscription
    • Contact
  • Advertise
  • Search
You are here: Home / Articles / Experts Discuss Proposed Giant Cell Arteritis Risk Tool

Experts Discuss Proposed Giant Cell Arteritis Risk Tool

April 26, 2018 • By Kathy Holliman

  • Tweet
  • Email
Print-Friendly Version / Save PDF
This image depicts severe arteritis of the coronary artery with inflammation and thrombosis, with extension into the myocardium.

This image depicts severe arteritis of the coronary artery with inflammation and thrombosis, with extension into the myocardium.

A proposed model to predict the risk of giant cell arteritis (GCA) prior to a temporal artery biopsy could help triage patients and guide decision making about the need for biopsy or monitoring (see Figure 1).

You Might Also Like
  • Giant Cell Arteritis
  • How to Manage Patients with Giant Cell Arteritis and Polymyalgia Rheumatica
  • Higher Fracture Risk in Patients with Polymyalgia Rheumatica, Giant-Cell Arteritis
Explore This Issue
April 2018
Also By This Author
  • 2014 ACR/ARHP Annual Meeting: Seeking the Patient Perspective in Real-World Settings

There’s no specific biomarker for GCA, and GCA can be a “diagnostic conundrum, especially when it presents in an occult or atypical fashion,” according to the researchers who published the development and validation data on their multivariable prediction model in a recent issue of Clinical Ophthalmology.1

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

Edsel Ing, MD, MPH, an ophthalmologist at Michael Garron Hospital and associate professor at the University of Toronto, and his colleagues note that even though several clinical prediction rules in the diagnosis and management of patients with suspected GCA exist, few were developed using more than 500 temporal artery biopsies or 100 biopsy-positive GCA cases, and few included external validation. The group’s research was compliant with the TRIPOD Initiative, a set of recommendations for reporting research that develops, validates or updates a prediction model so that bias risk and potential usefulness of the model can be adequately assessed.

The dearth of validated, TRIPOD-compliant prediction models for GCA that predict the risk prior to temporal artery biopsy prompted the research, Dr. Ing says. “GCA can be very difficult to diagnose without a biopsy. Sometimes, we look at blood tests, but how significant are the serology results compared with the patient’s symptoms? If a 60-year-old patient has a new-onset headache but blood tests are normal, compared to a 65-year-old patient with abnormal serology but no headache, determining the relative risk for GCA is problematic.”

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

Objective vs. Subjective Variables

Dr. Ing’s research analyzed the predictive value of objective and subjective variables that could potentially predict which patients are at higher risk of having biopsy-proven GCA. The investigators performed a retrospective review of case records of consecutive adult patients undergoing temporal artery biopsy for suspected GCA at seven secondary/tertiary care referral clinics. The researchers retrieved records from four medical centers in Canada, the U.S. and Switzerland. Forty-eight percent of the patients had been referred by ophthalmologists, and the rest by rheumatologists, internal medicine physicians or primary care centers.

All patients undergoing temporary artery biopsy for suspected GCA within two weeks of steroid initiation were eligible for the study. The pathologic diagnosis was considered the final diagnosis. Healed arteritis was considered positive for GCA in the research, and any case with an indeterminate pathologic diagnosis was considered negative for GCA. A review of 688 patients undergoing temporal artery biopsy yielded 530 cases with complete data. From the cohort of 530 cases, negative temporal artery biopsy results were reported for 397 patients and positive biopsies for 133 patients. The researchers performed multiple imputation for the missing data.

Pages: 1 2 3 4 5 6 | Single Page

Filed Under: Vasculitis Tagged With: Giant Cell Arteritis, VasculitisIssue: April 2018

You Might Also Like:
  • Giant Cell Arteritis
  • How to Manage Patients with Giant Cell Arteritis and Polymyalgia Rheumatica
  • Higher Fracture Risk in Patients with Polymyalgia Rheumatica, Giant-Cell Arteritis
  • Exciting Advances in Giant Cell Arteritis Diagnosis & Treatment

American College of Rheumatology

Visit the official website for the American College of Rheumatology.

Visit the ACR »

ACR Convergence

Don’t miss rheumatology’s premier scientific meeting for anyone involved in research or the delivery of rheumatologic care or services.

Visit the ACR Convergence site »

Rheumatology Research Foundation

The Foundation is the largest private funding source for rheumatology research and training in the U.S.

Learn more »

The Rheumatologist newsmagazine reports on issues and trends in the management and treatment of rheumatic diseases. The Rheumatologist reaches 11,500 rheumatologists, internists, orthopedic surgeons, nurse practitioners, physician assistants, nurses, and other healthcare professionals who practice, research, or teach in the field of rheumatology.

About Us / Contact Us / Advertise / Privacy Policy / Terms of Use / Cookie Preferences

  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed

Copyright © 2006–2023 American College of Rheumatology. All rights reserved.

ISSN 1931-3268 (print)
ISSN 1931-3209 (online)